Encompass Health (NYSE:EHC) Releases Earnings Results, Beats Expectations By $0.19 EPS

Encompass Health (NYSE:EHC) issued its quarterly earnings results on Wednesday. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19, Briefing.com reports. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. Encompass Health’s revenue was up 13.4% on a year-over-year basis. During the same period last year, the business posted $0.88 earnings per share. Encompass Health updated its FY24 guidance to $3.86-4.11 EPS.

Encompass Health Trading Up 0.1 %

Shares of EHC traded up $0.06 during trading hours on Thursday, hitting $82.86. The company had a trading volume of 472,170 shares, compared to its average volume of 659,412. The firm has a market cap of $8.30 billion, a P/E ratio of 23.57, a P/E/G ratio of 1.53 and a beta of 0.94. The stock’s 50 day moving average price is $77.89 and its 200 day moving average price is $70.67. The company has a quick ratio of 1.28, a current ratio of 1.28 and a debt-to-equity ratio of 1.19. Encompass Health has a 52-week low of $57.55 and a 52-week high of $85.84.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were given a dividend of $0.15 per share. The ex-dividend date was Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a yield of 0.72%. Encompass Health’s payout ratio is 17.29%.

Analyst Ratings Changes

A number of brokerages recently commented on EHC. Stephens reaffirmed an “overweight” rating and set a $85.00 price target on shares of Encompass Health in a research report on Tuesday, January 16th. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Barclays increased their price target on Encompass Health from $95.00 to $101.00 and gave the company an “overweight” rating in a research report on Thursday, March 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $83.00 target price on shares of Encompass Health in a research report on Friday, February 9th. Finally, Truist Financial raised their price target on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a report on Friday, February 9th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $84.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.